FDA Inspection 1265843 — Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc — FEI 3004865166

The FDA completed an inspection of Rigel Pharmaceuticals Inc on Mar 28, 2025 in South San Francisco, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Mar 28, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
South San Francisco, CA (United States)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.